Ocugen, Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing modifier gene therapies for retinal diseases. Form 8-K disclosures cover clinical and Regulation FD updates for programs including OCU410, capital-structure events such as warrant exercises and 6.75% convertible senior notes due 2034, and material agreements tied to the note indenture and loan repayment.
Proxy materials describe annual meeting proposals, shareholder voting matters, and governance practices. Other filings identify the company's common stock on The Nasdaq Capital Market, preliminary financial information, authorized-share validation matters, and furnished investor presentations containing forward-looking clinical-development statements.
Ocugen, Inc. officer Shankar Musunuri reported a proposed sale of 525,991 common shares through Merrill Lynch, with an aggregate market value of $497,964.91 and an approximate sale date of October 9, 2026. The notice also lists September 9, 2026 sales of 468,727 common shares by Musunuri and 57,264 common shares by KVM Holdings LLC.
Ocugen, Inc. (OCGN) adjourned its special meeting solely on a proposal to amend its charter to increase authorized common shares by 250,000,000. The adjourned meeting is scheduled for October 26, 2026, at 8:00 a.m. Eastern Time; July 27, 2026 remains the record date. Stockholders who already submitted a proxy or voted and do not want to change their vote on the proposal do not need to take any action.
Ocugen, Inc. (OCGN) adjourned its special meeting to October 5, 2026, solely to allow more time for stockholders to consider and vote on a proposal to increase authorized common stock by 250,000,000 shares. The company reported that 160,214,431 shares were represented at the September 21 meeting, constituting a quorum and equal to 47.3% of common stock outstanding as of July 27, 2026.
Stockholders approved the separate adjournment proposal with 124,584,658 votes for, 33,639,820 against and 1,989,953 abstentions. The adjourned meeting is scheduled for October 5, 2026, at 8:00 a.m. Eastern Time, virtually, and the July 27 record date remains in effect. Holders who previously submitted a proxy or voted and do not want to change their vote on Proposal 1 need take no action.
Ocugen, Inc. (OCGN) reported that Chief Executive Officer and director Shankar Musunuri sold a total of 525,991 shares of common stock on September 9, 2026 in open-market or private transactions pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2026.
The sales included 468,727 shares held directly at a weighted average price of $1.12 per share, with prices ranging from $1.06 to $1.31, and 57,264 shares held indirectly through KVM Holdings, LLC at a weighted average price of $1.12 per share, with prices ranging from $1.11 to $1.14. After these transactions, Musunuri held 4,487,197 shares directly and 1,088,035 shares indirectly through KVM Holdings, LLC, over which he has voting and investment power.
Ocugen, Inc. (OCGN) received notice that officer Shankar Musunuri plans to sell up to 525,991 shares of Ocugen common stock under Rule 144 through Merrill Lynch. The shares derive from multiple equity compensation grants between February 2014 and January 2026 and have an aggregate market value of $589,741.11.
Ocugen, Inc. (OCGN) reported the start of dosing for the first patient in its global Phase 3 registrational trial of OCU410, a modifier gene therapy candidate for geographic atrophy secondary to dry age-related macular degeneration, following an FDA Type B End-of-Phase 2 meeting that aligned on a single pivotal trial design to support a future Biologics License Application.
The company also highlighted that the FDA granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) designation in July 2026. Separately, an independent Data Monitoring Committee completed a pre-specified interim analysis of the Phase 2/3 OCU410ST trial in 26 subjects and recommended modifying and continuing the study to obtain 8‑month follow-up data for the full population, despite noting a negative direction of treatment effect in the small interim sample and a baseline lesion size imbalance between arms.
Janus Henderson Group Ltd. reports beneficial ownership of Ocugen, Inc. common stock on a passive basis through its asset management subsidiaries. The asset managers may be deemed the beneficial owner of 10,000,000 Ocugen common stock, including 10,000,000 warrants, representing 3.0% of the common stock class as of June 30, 2026.
All voting and dispositive authority over these securities is held on a shared basis, with no sole voting or dispositive power reported. Economic benefits belong to the underlying managed portfolios, which receive all dividends and sale proceeds, and none of those individual portfolios holds more than five percent of Ocugen’s common stock.
State Street Corporation reported a significant ownership stake in Ocugen Inc. common stock. State Street beneficially owns 21,469,307 shares of Ocugen common stock, representing 6.3% of the class as of June 30, 2026.
State Street reports no sole voting or dispositive power over these shares. It has shared voting power over 21,055,589 shares and shared dispositive power over 21,469,307 shares, largely through its asset management subsidiaries SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company.
Ocugen, Inc., a gene therapy biotechnology company, reported continued operating losses and significant financing activity for the quarter ended June 30, 2026. Collaborative arrangement revenue was modest at $1.5 million for the quarter and $3.0 million for the first half of 2026, while research and development and general and administrative expenses drove a quarterly net loss of $24.9 million and a year-to-date net loss of $44.1 million.
Cash and cash equivalents increased to $100.1 million from $18.6 million at year-end, primarily due to a January underwritten offering, warrant exercises, and a May private offering of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034. About $32.7 million of the note proceeds were used to fully repay and terminate a prior term loan; the remainder is for general corporate purposes. The new convertible notes, together with an associated $33.7 million derivative liability, are classified as current liabilities pending shareholder approval to increase authorized shares.
Despite the strengthened cash position, Ocugen has an accumulated deficit of $452.1 million, negative stockholders’ equity of $16.6 million, and used $34.0 million of cash in operating activities in the first half of 2026. Management concluded there is substantial doubt about the company’s ability to continue as a going concern within one year after the financial statements’ issuance and is evaluating additional capital raises, spending adjustments, and strategic options.
Ocugen, Inc. reported second quarter 2026 results and provided a business update. Collaborative arrangement revenue was $1,488 thousand for the quarter and $3,022 thousand for the first half of 2026, compared with $1,373 thousand and $2,854 thousand in the prior-year periods.
The company recorded a net loss of $24,877 thousand for Q2 2026 and $44,054 thousand for the first six months of 2026, versus $14,739 thousand and $30,089 thousand a year earlier. As of June 30, 2026, cash was $100,051 thousand and total assets were $124,206 thousand, with negative stockholders' equity of $16,556 thousand.
Management highlighted closing a $130 million convertible senior notes financing, which added convertible notes and a derivative liability of $82,359 thousand and $33,708 thousand, respectively, and stated that this financing extends Ocugen’s cash runway into 2028. The update also emphasized late-stage gene therapy programs OCU410, OCU410ST, and OCU400 targeting serious retinal diseases.